Flagship peptide screening profile

Tesamorelin

A ranked discovery registry is available. No legacy governed direct-evidence relationship has yet been promoted for this profile; the zero below is intentional and must not be interpreted as evidence of absence.

global evidence atlas

Tesamorelin research, ranked and separated by purpose

This is a deduplicated PubMed screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

104Discoverable PubMed universe

104Ranked screening records

13Research domains

0Governed direct evidence relationships

SearchDomainEvidence class

104 matching records · ranked 2026-09-18

Page 1 of 5

#1Proposed tier Ameta analysisAwaiting human appraisal

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

Obesity research & clinical practice · 2026 Jan-Feb · PMID 41545261 · DOI 10.1016/j.orcp.2026.01.002

HIV-associated lipodystrophy · Visceral adipose tissue · MASH and liver · Growth-hormone axis · Metabolic and glycemic outcomes · Safety and tolerability

#2Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.

Journal of the International Association of Providers of AIDS Care · 2026 Jan-Dec · PMID 42538058 · DOI 10.1177/23259582261475549

HIV-associated lipodystrophy · Safety and tolerability

#3Proposed tier Arandomized trialAwaiting human appraisal

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

The Journal of infectious diseases · 2025 Jun 2 · PMID 39813152 · DOI 10.1093/infdis/jiaf012

HIV-associated lipodystrophy · Cognitive and neurologic outcomes

#4Proposed tier Arandomized trialAwaiting human appraisal

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

AIDS (London, England) · 2024 Oct 1 · PMID 38905488 · DOI 10.1097/QAD.0000000000003965

HIV-associated lipodystrophy · Safety and tolerability

#5Proposed tier Arandomized trialAwaiting human appraisal

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021 Aug 16 · PMID 33852720 · DOI 10.1093/cid/ciab019

HIV-associated lipodystrophy · MASH and liver · Growth-hormone axis

#6Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Journal of acquired immune deficiency syndromes (1999) · 2010 Mar · PMID 20101189 · DOI 10.1097/QAI.0b013e3181cbdaff

HIV-associated lipodystrophy · Visceral adipose tissue · Growth-hormone axis · Long-term outcomes · Safety and tolerability

#7Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

The Journal of clinical endocrinology and metabolism · 2010 Sep · PMID 20554713 · DOI 10.1210/jc.2010-0490

Visceral adipose tissue · Growth-hormone axis · Long-term outcomes · Safety and tolerability · Ongoing development

#8Proposed tier Arandomized trialAwaiting human appraisal

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

AIDS (London, England) · 2008 Sep 12 · PMID 18690162 · DOI 10.1097/QAD.0b013e32830a5058

HIV-associated lipodystrophy · Visceral adipose tissue · Growth-hormone axis · Long-term outcomes · Safety and tolerability

#9Proposed tier Arandomized trialAwaiting human appraisal

Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021 Jun 15 · PMID 32270862 · DOI 10.1093/cid/ciaa382

MASH and liver

#10Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

JCI insight · 2020 Aug 20 · PMID 32701508 · DOI 10.1172/jci.insight.140134

HIV-associated lipodystrophy · MASH and liver

#11Proposed tier Asystematic reviewAwaiting human appraisal

Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

HIV medicine · 2011 Sep · PMID 21265979 · DOI 10.1111/j.1468-1293.2010.00906.x

HIV-associated lipodystrophy · Growth-hormone axis

#12Proposed tier Arandomized trialAwaiting human appraisal

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

The Journal of frailty & aging · 2019 · PMID 31237318 · DOI 10.14283/jfa.2018.45

HIV-associated lipodystrophy · Growth-hormone axis

#13Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

The lancet. HIV · 2019 Dec · PMID 31611038 · DOI 10.1016/S2352-3018(19)30338-8

HIV-associated lipodystrophy · MASH and liver

#14Proposed tier Arandomized trialAwaiting human appraisal

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

PloS one · 2017 · PMID 28617838 · DOI 10.1371/journal.pone.0179538

Growth-hormone axis · Metabolic and glycemic outcomes · Safety and tolerability

#15Proposed tier Arandomized trialAwaiting human appraisal

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

PloS one · 2015 · PMID 26457580 · DOI 10.1371/journal.pone.0140358

HIV-associated lipodystrophy · Visceral adipose tissue · Growth-hormone axis

#16Proposed tier Arandomized trialAwaiting human appraisal

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

JAMA · 2014 Jul 23-30 · PMID 25038357 · DOI 10.1001/jama.2014.8334

HIV-associated lipodystrophy · Visceral adipose tissue · MASH and liver

#17Proposed tier Arandomized trialAwaiting human appraisal

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012 Jun · PMID 22495074 · DOI 10.1093/cid/cis251

HIV-associated lipodystrophy · Visceral adipose tissue · Metabolic and glycemic outcomes

#18Proposed tier Arandomized trialAwaiting human appraisal

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

The New England journal of medicine · 2007 Dec 6 · PMID 18057338 · DOI 10.1056/NEJMoa072375

HIV-associated lipodystrophy · Growth-hormone axis · Metabolic and glycemic outcomes

#19Proposed tier Arandomized trialAwaiting human appraisal

A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

AIDS (London, England) · 2005 Aug 12 · PMID 16052083 · DOI 10.1097/01.aids.0000180099.35146.30

HIV-associated lipodystrophy · Visceral adipose tissue · Growth-hormone axis

#20Proposed tier Arandomized trialAwaiting human appraisal

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2017 Dec · PMID 29031905 · DOI 10.1016/j.ghir.2017.10.002

MASH and liver · Growth-hormone axis

#21Proposed tier Arandomized trialAwaiting human appraisal

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

Clinical pharmacokinetics · 2015 Mar · PMID 25358450 · DOI 10.1007/s40262-014-0202-x

HIV-associated lipodystrophy · Mechanism and pharmacology

#22Proposed tier Arandomized trialAwaiting human appraisal

Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.

JAMA neurology · 2013 Jul · PMID 23689947 · DOI 10.1001/jamaneurol.2013.1425

Growth-hormone axis · Cognitive and neurologic outcomes

#23Proposed tier Arandomized trialAwaiting human appraisal

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.

Archives of neurology · 2012 Nov · PMID 22869065 · DOI 10.1001/archneurol.2012.1970

Growth-hormone axis · Cognitive and neurologic outcomes

#24Proposed tier Arandomized trialAwaiting human appraisal

Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

The Journal of clinical endocrinology and metabolism · 2012 Dec · PMID 23015655 · DOI 10.1210/jc.2012-2794

Growth-hormone axis · Metabolic and glycemic outcomes

#25Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

AIDS (London, England) · 2011 Jun 19 · PMID 21516030 · DOI 10.1097/QAD.0b013e328347f3f1

HIV-associated lipodystrophy · Visceral adipose tissue

Count reconciliation: 104 discoverable PubMed records match the peptide identity query; 104 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Governed direct evidence relationships.” Domain totals overlap because one publication may inform several questions.

Loading research intelligence

Preparing the structured Flagship evidence library.

Flagship peptide screening profile

Tesamorelin

global evidence atlas

Tesamorelin research, ranked and separated by purpose

This is a deduplicated PubMed screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

104Discoverable PubMed universe

104Ranked screening records

13Research domains

0Governed direct evidence relationships

SearchDomainEvidence class

104 matching records · ranked 2026-09-18

Page 1 of 5

#1Proposed tier Ameta analysisAwaiting human appraisal

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.

Obesity research & clinical practice · 2026 Jan-Feb · PMID 41545261 · DOI 10.1016/j.orcp.2026.01.002

HIV-associated lipodystrophy · Visceral adipose tissue · MASH and liver · Growth-hormone axis · Metabolic and glycemic outcomes · Safety and tolerability

#2Proposed tier Ameta analysisAwaiting human appraisal

Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.

Journal of the International Association of Providers of AIDS Care · 2026 Jan-Dec · PMID 42538058 · DOI 10.1177/23259582261475549

HIV-associated lipodystrophy · Safety and tolerability

#3Proposed tier Arandomized trialAwaiting human appraisal

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.

The Journal of infectious diseases · 2025 Jun 2 · PMID 39813152 · DOI 10.1093/infdis/jiaf012

HIV-associated lipodystrophy · Cognitive and neurologic outcomes

#4Proposed tier Arandomized trialAwaiting human appraisal

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.

AIDS (London, England) · 2024 Oct 1 · PMID 38905488 · DOI 10.1097/QAD.0000000000003965

HIV-associated lipodystrophy · Safety and tolerability

#5Proposed tier Arandomized trialAwaiting human appraisal

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021 Aug 16 · PMID 33852720 · DOI 10.1093/cid/ciab019

HIV-associated lipodystrophy · MASH and liver · Growth-hormone axis

#6Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Journal of acquired immune deficiency syndromes (1999) · 2010 Mar · PMID 20101189 · DOI 10.1097/QAI.0b013e3181cbdaff

HIV-associated lipodystrophy · Visceral adipose tissue · Growth-hormone axis · Long-term outcomes · Safety and tolerability

#7Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

The Journal of clinical endocrinology and metabolism · 2010 Sep · PMID 20554713 · DOI 10.1210/jc.2010-0490

Visceral adipose tissue · Growth-hormone axis · Long-term outcomes · Safety and tolerability · Ongoing development

#8Proposed tier Arandomized trialAwaiting human appraisal

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

AIDS (London, England) · 2008 Sep 12 · PMID 18690162 · DOI 10.1097/QAD.0b013e32830a5058

HIV-associated lipodystrophy · Visceral adipose tissue · Growth-hormone axis · Long-term outcomes · Safety and tolerability

#9Proposed tier Arandomized trialAwaiting human appraisal

Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021 Jun 15 · PMID 32270862 · DOI 10.1093/cid/ciaa382

MASH and liver

#10Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

JCI insight · 2020 Aug 20 · PMID 32701508 · DOI 10.1172/jci.insight.140134

HIV-associated lipodystrophy · MASH and liver

#11Proposed tier Asystematic reviewAwaiting human appraisal

Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

HIV medicine · 2011 Sep · PMID 21265979 · DOI 10.1111/j.1468-1293.2010.00906.x

HIV-associated lipodystrophy · Growth-hormone axis

#12Proposed tier Arandomized trialAwaiting human appraisal

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

The Journal of frailty & aging · 2019 · PMID 31237318 · DOI 10.14283/jfa.2018.45

HIV-associated lipodystrophy · Growth-hormone axis

#13Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

The lancet. HIV · 2019 Dec · PMID 31611038 · DOI 10.1016/S2352-3018(19)30338-8

HIV-associated lipodystrophy · MASH and liver

#14Proposed tier Arandomized trialAwaiting human appraisal

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

PloS one · 2017 · PMID 28617838 · DOI 10.1371/journal.pone.0179538

Growth-hormone axis · Metabolic and glycemic outcomes · Safety and tolerability

#15Proposed tier Arandomized trialAwaiting human appraisal

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

PloS one · 2015 · PMID 26457580 · DOI 10.1371/journal.pone.0140358

HIV-associated lipodystrophy · Visceral adipose tissue · Growth-hormone axis

#16Proposed tier Arandomized trialAwaiting human appraisal

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

JAMA · 2014 Jul 23-30 · PMID 25038357 · DOI 10.1001/jama.2014.8334

HIV-associated lipodystrophy · Visceral adipose tissue · MASH and liver

#17Proposed tier Arandomized trialAwaiting human appraisal

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012 Jun · PMID 22495074 · DOI 10.1093/cid/cis251

HIV-associated lipodystrophy · Visceral adipose tissue · Metabolic and glycemic outcomes

#18Proposed tier Arandomized trialAwaiting human appraisal

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

The New England journal of medicine · 2007 Dec 6 · PMID 18057338 · DOI 10.1056/NEJMoa072375

HIV-associated lipodystrophy · Growth-hormone axis · Metabolic and glycemic outcomes

#19Proposed tier Arandomized trialAwaiting human appraisal

A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

AIDS (London, England) · 2005 Aug 12 · PMID 16052083 · DOI 10.1097/01.aids.0000180099.35146.30

HIV-associated lipodystrophy · Visceral adipose tissue · Growth-hormone axis

#20Proposed tier Arandomized trialAwaiting human appraisal

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2017 Dec · PMID 29031905 · DOI 10.1016/j.ghir.2017.10.002

MASH and liver · Growth-hormone axis

#21Proposed tier Arandomized trialAwaiting human appraisal

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

Clinical pharmacokinetics · 2015 Mar · PMID 25358450 · DOI 10.1007/s40262-014-0202-x

HIV-associated lipodystrophy · Mechanism and pharmacology

#22Proposed tier Arandomized trialAwaiting human appraisal

Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging.

JAMA neurology · 2013 Jul · PMID 23689947 · DOI 10.1001/jamaneurol.2013.1425

Growth-hormone axis · Cognitive and neurologic outcomes

#23Proposed tier Arandomized trialAwaiting human appraisal

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.

Archives of neurology · 2012 Nov · PMID 22869065 · DOI 10.1001/archneurol.2012.1970

Growth-hormone axis · Cognitive and neurologic outcomes

#24Proposed tier Arandomized trialAwaiting human appraisal

Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

The Journal of clinical endocrinology and metabolism · 2012 Dec · PMID 23015655 · DOI 10.1210/jc.2012-2794

Growth-hormone axis · Metabolic and glycemic outcomes

#25Proposed tier Arandomized trialAwaiting human appraisal

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

AIDS (London, England) · 2011 Jun 19 · PMID 21516030 · DOI 10.1097/QAD.0b013e328347f3f1

HIV-associated lipodystrophy · Visceral adipose tissue